You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tisagenlecleucel

Showing 1 - 25 of 37
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)

Active, not recruiting
  • Mantle Cell Lymphoma Recurrent
  • ibrutinib and Tisagenlecleucel
  • Melbourne, Victoria, Australia
    Peter Mac Callum Cancer Centre
Nov 4, 2022

Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

Terminated
  • Diffuse Large B-cell Lymphoma
  • Tampa, Florida
  • +1 more
Jan 27, 2023

Among Patients Treated With Tisagenlecleucel

Completed
  • Diffuse Large B-cell Lymphoma
  • Tisagenlecleucel
  • East Hanover, New Jersey
    Novartis Investigative Site
Sep 13, 2022

Tisagenlecleucel in Brazilian Acute Lymphoblastic Leukemia or

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • tisagenlecleucel
  • (no location specified)
Sep 13, 2022

B-cell Acute Lymphoblastic Leukemia Trial in New York (Tisagenlecleucel)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 13, 2022

B-cell Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel)

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • (no location specified)
Feb 3, 2022

Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint

Recruiting
  • Refractory Diffuse Large B-cell Lymphoma
  • +4 more
  • Tisagenlecleucel
  • Duarte, California
  • +2 more
Aug 9, 2022

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Cologne, Germany
  • +1 more
Mar 2, 2022

Lymphoma, Large B-Cell, Diffuse Trial (Cyclophosphamide, TLI, Fludarabine)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • (no location specified)
Aug 18, 2023

B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial (Decreasing starting times for beginning

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia, in Relapse
  • Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
  • Nivolumab starting at day -1
  • (no location specified)
Apr 4, 2022

Follicular Lymphoma Trial in Worldwide (tisagenlecleucel)

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • tisagenlecleucel
  • Duarte, California
  • +29 more
Nov 2, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Trial in Canada, Japan (CTL019)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Diffuse Large B-cell Lymphoma
  • CTL019
  • Hamilton, Ontario, Canada
  • +41 more
Oct 17, 2022

Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma Trial in Boston (Tisagenlecleucel)

Recruiting
  • Primary CNS Lymphoma
  • +2 more
  • Tisagenlecleucel
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 18, 2021

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Recruiting
  • Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Nov 2, 2022

Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
  • Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
  • La Jolla, California
  • +66 more
Jan 6, 2023

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel, Blinatumomab, Inotuzumab)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • +2 more
  • (no location specified)
Jul 7, 2020

Diffuse Large B Cell Lymphoma Trial (Bridging Radiotherapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Bridging Radiotherapy
  • Leeds, United Kingdom
  • +2 more
Dec 6, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)

Completed
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • Lymphodepleting chemotherapy
  • San Francisco, California
  • +25 more
Jan 27, 2023

B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic

Completed
Has Results
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CTL019 T-cells
  • Los Angeles, California
  • +12 more
Oct 29, 2020

People Living With HIV Treated With CD19-directed CAR T Cell

Active, not recruiting
  • Leukemia
  • +9 more
    • Philadelphia, Pennsylvania
      Pennsylvania Hospital
    Mar 29, 2023

    CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

    Not yet recruiting
    • Lymphoma
    • Chimeric Antigen Receptor
    • (no location specified)
    Oct 24, 2023